AIM ImmunoTech expands Ampligen Long COVID patent protection across Europe, UK through 2041
AIM•Context from prior patent disclosure
Disclosure follows a newly issued U.S. patent covering Ampligen combined with pembrolizumab for cancer treatment.
Expanded patent protection for Ampligen in Europe and the UK
AIM ImmunoTech expanded Ampligen patent protection in Europe and the UK for treating Long COVID, with coverage expected through June 2041.
Protection covers three forms of patent rights, with the European opposition window closing Aug. 25, 2026 with no challenge filed.
Claims cover therapeutic dsRNA use, including dosing regimens and intranasal, intravenous, or inhalation delivery methods.
